Moleculin Biotech Inc (MBRX)

[lucky, mydog]

11. Moleculin received a deficiency letter from NASDAQ on March 20, 2020
because its bid price for the company’s common stock closed under $1.00 over the preceding
thirty consecutive business days in violation of NASDAQ Listing Rule 5550(a)(2). The
company reported in a Form 8-K filed with the Commission on April 23, 2020 that it had
regained compliance with the rule because the bid price closed above $1.00 for ten consecutive
business days during the period from April 8 through April 22, 2020. Moleculin’s ability to
regain compliance with NASDAQ listing requirements coincides with its statements regarding a
potential treatment for COVID-19

https://www.sec.gov/litigation/apdocuments/3-19801-event-2020-05-21-information-before-the-commisson-at-the-time-of-trading-suspension.pdf